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Abstract 
Three-dimensional QSAR studies for substituted aryloxazolidinones 3–9 were conducted using 
TSAR 3.3. The in vitro activities (MICs) of the compounds against Staphylococcus aureus and 
Enterococcus faecalis exhibited a good correlation with the prediction made by the model using 
heat of formation and LUMO energies. 
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Introduction 
 
Multidrug resistant Gram-positive bacteria continue to pose challenges to the medicinal 
chemistry community.1 Linezolid 1, marketed as Zyvox®, is an oxazolidinone class of 
antibacterial, approved for treating mostly Gram-positive bacterial infections, especially 
methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus Epidermidis (MRSE) and 
vancomycin resistant enterococci (VRE).2 Another early clinical candidate, Eperezolid 2, was 
discontinued from development after phase I clinical trials. While much research has been aimed 
at the development of novel oxazolidinones, no new members of this class have achieved 
regulatory approval. 
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 In the past, some efforts have been made to understand the structure-activity relationships of 
oxazolidinone antibacterial agents using comparative molecular field analysis (CoMFA), 3D-
QSAR and QSPR methods.3 We have already reported 3D-QSAR studies for N-4-
General Papers                                                                                                             ARKIVOC 2006 (xvi) 109-121 
ISSN 1424-6376                                                                 Page 110                                                               ©ARKAT 
arylacryloylpiperazin-1-yl-phenyl-oxazolidinones 3–7 using TSAR 3.3.4 The in vitro 
antibacterial activities (MICs) of compounds 3–7 against Staphylococcus aureus ATCC 25923 
exhibited a strong correlation with the prediction made by our model. It was observed that the 
activity of the compounds increases when the energy of the LUMO (Lowest Unoccupied 
Molecular Orbital) is lower and the heat of formation (HOF) is higher. Thus, compounds which 
have lower HOF become less active and, similarly, compounds having low LUMO energies are 
the most active and the activity decreases as the LUMO energy increases. 
 We decided to examine if our model (Equation 1)4 can predict the antibacterial activity trends 
of different sets of compounds 8–9 for the same strain (S. aureus ATCC 25923) as well as in a 
different strain such as Enterococcus faecalis (E. fa) ATCC 29212.  
Log (1/C) = 0.006919662*HOF – 0.72196823*LUMO – 0.034151886*Polarization YY + 
0.0004945533*Octupole XYZ + 4.8290181       (1) 
 The present study aims to validate if compounds 8–9 follow the same parameters for the 
prediction of their activity, namely, that lower HOF and lower LUMO energies result in more 
potent antibacterial compounds. 
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Results and Discussion 
 
Based on Equation 1, developed using the training set of compounds reported earlier by us,4 
calculations were done for a set of parameters for compounds 8a to 8aa, which is shown in Table 
1. A reasonable correlation between the predicted MICs by Equation 1 and the experimental 
MICs reported by Das et al.5 was observed. 
 The predicted MICs, especially for 8h, 8i, 8j, 8m, 8n, 8q, 8r and 8u, were found to be 8- to 
16-fold different from the experimental values. In view of the fact that, generally, reported MICs 
may vary from laboratory to laboratory by a factor of one dilution (i.e. 2 to 4 or 4 to 8), but some 
of the above compounds (8h, 8i, 8j, 8m and 8r) needed special deliberation. 
 Therefore, a new equation (Equation 2) was developed using randomly selected compounds 
from the training set shown in Table 1 and then used to predict the MIC values for the test 
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compounds 8b, 8h, 8i, 8j, 8m, 8n, 8q, 8r and 8u. However, the data sets are not suited for QSAR 
analysis because compounds 8 have very small variance in the biological activities. Nonetheless 
we wanted to validate the hypothesis that the antibacterial activities follow a trend based on HOF 
and LUMO energies. The new 3D QSAR model that was obtained is:  
Log (1/C) = 0.0068*X1 – 0.7457*X2 + 2.5496        (2) 
where X1 is Heat of Formation and X2 is LUMO and the statistical parameters for above 
Equation 2 are: s value = 0.2614; F = 18.3399; regression coefficient  
r = 0.8507; r^2 = 0.7237; cross validation, r^2(CV) = 0.6045. 
 
 With the help of Equation 2, we predicted MIC values for all the compounds (shown in Table 
1). Surprisingly, it was found that the predicted MIC values based on both Equations 1 and 2 
were significantly different from the experimental values for the same set of compounds (8h, 8i, 
8j, 8m, 8n, 8q, 8r and 8u). Thus, a re-examination of the SAR of these compounds was done and 
it was found that both Equations 1 and 2 are not capable of predicting the difference between the 
positional isomers. For example, when we compare 8g, 8q and 8r, the predicted MICs remain 
more or less the same (8g, 1.33; 8q, 1.06; 8r, 0.6 µg/mL), whereas observed MIC values vary 
significantly (8g, 1; 8q, 8; 8r, 8 µg/mL). Furthermore, the equation appears to be inadequate, 
especially for compounds having powerful electron withdrawing groups such as CN (8h: 
observed MIC of 16 vs. 0.8 µg/mL predicted with Equation 1 or 2.24 µg/mL predicted with 
Equation 2) or NO2 (8n: observed MIC of 16 v/s 1.48 µg/mL predicted with Equation 1 or 2.10 
µg/mL predicted with Equation 2) (see Table 1). 
 We also considered that it would be interesting to study if Equation 1 can predict the activity 
of compounds with a different structural scaffold. Therefore, a study of compounds 9a to 9ac, as 
reported by Jang et al.6 (Table 2), was undertaken. A very good correlation between the 
predicted MIC using Equation 1 and the observed MIC (compound 9d to 9ac) was found, except 
for compounds 9a–9c (observed MIC >64 µg/mL versus predicted MIC 2–3 µg/mL). Another 
equation was developed using 23 compounds listed in Table 2 as training set in order to predict 
the MIC of the remaining test compounds 9m, 9o, 9s, 9v, 9ab and 9ac. However, the data sets 
are not suited for QSAR analysis because they have significantly different R1 residues and 15 
compounds have very small variance in the biological activities. However, we wanted to 
investigate if compounds with a different scaffold that have antibacterial activities follow a trend 
based on HOF and LUMO energies. 
The 3D QSAR model developed is as follows:  
Log (1/C) = 0.0070*X1 – 3.1117*X2 – 0.1317*X3 + 9.3684     (3) 
where X1 is Heat of Formation, X2 is LUMO and X3 is Polarization YY and the statistical 
parameters for above Equation 3 are: s value = 0.4182; F = 34.5641; regression coefficient r = 
0.9193; r^2 = 0.8451; cross validation, r^2(CV) = 0.7246.  
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Table 1. Prediction of antibacterial activity of piperazinylphenyloxazolidinone5 
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8a piperazine 5-furan –138.857 –0.483 57.547 51.640 –23.679 8 2.33 4.52 8 11.481 
8b piperazine 
5-furan-2-
carbaldehyde 
–171.408 –0.523 59.461 –41.400 –16.974 1 3.37 7.45 8 22.545 
8c piperazine 
5-furan-2-
carboxylic acid 
–226.546 –0.548 60.518 143.518 –36.220 >16 8.44 17.65 >16 14.266 
8d piperazine 
ethyl 5-furan-2-
carboxylate 
–223.475 –0.536 66.271 162.936 –50.090 >16 15.49 21.07 >16 14.492 
8e piperazine 
5-furan-2-
carbaldehyde 
oxime 
–129.767 –0.500 60.600 53.342 –17.558 2 3.25 4.21 8 10.688 
8f piperazine 
(5-furan-2-
ylmethylene)-
hydrazine 
–101.315 –0.541 62.199 –156.048 30.532 2 1.69 2.50 8 18.187 
8g piperazine 2-nitro-5-furan –145.305 –1.030 58.786 7.109 –3.658 1 1.33 1.96 2 2.306 
8h piperazine 
5-furan-2-
carbonitrile 
–100.149 –0.566 61.492 45.497 –11.147 16 0.80 2.24 16 6.386 
8i piperazine 2-bromo-5-furan –125.693 –0.499 58.659 70.605 –24.257 >16 1.29 4.21 >16 10.425 
8j piperazine 2-chloro-5-furan –142.786 –0.498 58.827 60.863 –34.639 >16 2.56 5.06 >16 12.064 
8k piperazine 
5-furan-2-
ylmethanol 
–182.986 –0.491 61.661 53.422 7.415 >16 5.90 9.77 >16 15.940 
8l piperazine 
5-furan-2-
ylmethyl acetate 
–225.982 –0.500 65.699 85.765 –19.444 >16 17.08 20.20 >16 22.807 
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8m piperazine 2-methyl-5-furan –147.575 –0.474 60.600 50.328 –24.345 >16 3.55 5.42 >16 13.368 
8n piperazine 
2-nitro-5-
thiophene 
–107.413 –1.561 61.037 202.343 –153.299 8 0.45 0.48 8 0.152 
8o piperazine 
2-nitro-1H-
pyrrole 
–122.936 –0.705 58.010 195.402 –377.869 4 1.11 3.05 4 7.286 
8p piperazine 
1-methyl-2-nitro-
1H-pyrrole 
–122.267 –0.664 60.509 240.185 –376.542 4 1.49 3.13 4 6.822 
8q piperazine 2–nitro-4-furan –146.711 –1.068 56.872 228.770 –308.339 8 1.06 2.04 8 1.691 
8r piperazine 2-nitro-3-furan –145.417 –1.007 58.153 –55.671 66.159 8 0.60 2.24 4 2.788 
8s 1,4-diazepane 2-nitro-5-furan –146.145 –1.133 60.568 –1.087 –15.551 2 2.17 2.21 2 1.804 
8t 
2-methyl-
piperazine 
2-nitro-5-furan –150.401 –1.117 61.356 –23.419 –403.063 4 1.62 2.39 4 7.543 
8u 
(2S,6R)-2,6-
dimethyl-
piperazine 
2-nitro-5-furan –156.006 –1.152 61.695 –272.272 374.691 16 1.48 2.10 8 2.260 
8v 
N-methylpiperi-
din-4-amine 
2-nitro-5-furan –153.601 –1.036 67.825 –37.910 321.593 1 2.91 2.59 0.5 1.169 
8w 
N-(piperidin-4-
yl)acetamide 
2-nitro-5-furan –192.507 –1.412 68.340 300.223 –533.654 >16 5.97 5.54 >16 1.192 
8x piperidin-4-amine 2-nitro-5-furan –154.942 –1.151 64.747 239.549 –70.990 1 2.66 2.03 0.5 0.626 
8y 
N,3-dimethyl-
piperidin-4-amine 
2-nitro-5-furan –156.755 –1.073 68.380 93.588 257.501 >16 3.28 2.91 >16 0.671 
8z 
(1R,5S,6S)-N-
methyl-3-aza-
bicyclo[3.1.0]-
hexan-6-amine 
2-nitro-5-furan –121.769 –1.109 64.627 –99.094 –59.585 2 0.60 1.26 2 3.090 
8aa 
1-((1R,5S,6S)-3-
azabicyclo-
[3.1.0]hexan-6-
yl)-N-methyl-
methanamine 
2-nitro-5-furan –123.913 –1.020 56.622 –307.942 545.798 2 0.94 1.36 2 1.943 
a MIC = Minimum Inhibitory Concentration for inhibition of the organism shown in µg/mL. 
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Table 2. Prediction of antibacterial activity of arylpiperazinyloxazolidinones with diversification 
of the N-substituents6 
N
O
O
R1
NNR3
Z
R2
9  
 
S. aureus ATCC 25923 
E. faecalis 
ATCC 29212 
C
om
po
un
d 
R1 R2 R3 Z 
H
ea
t o
f f
or
m
at
io
n 
LUMO 
Po
la
riz
at
io
n 
Y
Y
 
Octupole 
XXZ 
Octupole 
ZZZ 
Ex
pe
rim
en
ta
l M
IC
 
(µ
g/
m
L)
 a
Pr
ed
ic
te
d 
M
IC
 
(µ
g/
m
L)
 a
 u
si
ng
 E
qu
at
io
n 
13
 
Pr
ed
ic
te
d 
M
IC
 
( µ
g/
m
L)
 a
 u
si
ng
 E
qu
at
io
n 
3 
Ex
pe
rim
en
ta
l M
IC
 
(µ
g/
m
L)
 a
Pr
ed
ic
te
d 
M
IC
 
( µ
g/
m
L)
 a 
us
in
g 
Eq
ua
tio
n 
4 
9a 
2-methoxy-
pyridine 
F 2-Cl H –69.019 –0.419 70.618 68.974 
–
207.536
>64 3.22 67.46 >64 14.634 
9b 
2-methoxy-
pyrazine 
F 2-Cl H 
–
100.901 
–0.410 67.409 –379.687
–
172.397
>64 2.12 22.62 >64 185.924
9c 
2-methoxy-
isoxazole 
F 2-Cl H –98.002 –0.501 81.799 41.964 –77.933 >64 3.00 30.92 >64 10.608 
9d N(C=S)CH3 F H H –36.293 –1.055 67.886 320.895 162.382 0.12 0.40 0.15 0.25 0.087 
9e N(C=S)CH3 F H N –31.694 –1.056 65.982 297.511 165.477 0.06 0.36 0.08 0.25 0.093 
9f N(C=S)CH3 F 2-Cl H –42.042 –1.053 67.427 307.289 153.329 0.12 0.45 0.14 >64 0.109 
9g N(C=S)CH3 F 3-Cl H –42.990 –1.070 66.361 359.197 153.518 0.03 0.46 0.10 0.06 0.079 
9h N(C=S)CH3 F 4-Cl H –43.045 –1.074 69.28 361.560 148.908 0.12 0.53 0.28 0.25 0.079 
9i N(C=S)CH3 F 2-Me H –44.127 –1.054 64.812 244.794 152.541 0.12 0.23 0.06 0.05 0.147 
9j N(C=S)CH3 F 3-F H –79.860 –1.076 73.26 249.192 131.178 0.12 0.80 0.27 0.03 0.198 
9k 
N(C=S)SCH
3 
F H N –24.710 –1.306 70.282 148.124 190.185 0.06 0.33 0.04 0.12 0.078 
9l 
N(C=S)SCH
3 
F 3-Cl H –36.025 –1.326 67.367 193.399 167.930 0.12 0.40 0.04 0.5 0.073 
9m 
N(C=S)SCH
3 
H 3-OMe H –25.941 –1.238 74.426 183.617 104.352 0.12 0.48 0.16 0.12 0.112 
9n 
N(C=S)SCH
3 
F 2-Me H –37.149 –1.314 59.888 94.165 152.022 0.12 0.34 0.07 0.12 0.129 
9o N(C=S)NH2 H H H 9.138 –0.840 68.874 188.741 289.331 0.12 0.21 0.28 0.12 0.157 
9p N(C=S)NH2 F H H –32.270 –0.902 60.916 262.294 351.767 0.06 0.35 0.06 0.12 0.107 
9q N(C=S)NH2 F 2-OMe H –67.144 –0.880 68.165 184.144 347.193 0.25 0.88 0.89 0.25 0.257 
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9r N(C=S)NH2 F H N –27.651 –0.899 59.444 253.605 361.004 0.12 0.32 0.05 0.25 0.106 
9s N(C=S)NH2 H 2-Cl H 3.343 –0.833 69.131 165.825 270.297 0.03 0.26 0.39 0.06 0.220 
9t N(C=S)NH2 F 2-Cl H –38.004 –0.891 60.58 267.692 340.235 0.12 0.40 0.05 0.25 0.128 
9u N(C=S)NH2 F 3-Cl H –38.968 –0.915 60.009 306.873 368.777 0.02 0.39 0.05 0.06 0.088 
9v N(C=S)NH2 F 3-OMe H –70.177 –0.893 65.554 292.509 363.029 0.03 0.93 0.40 0.06 0.137 
9w N(C=S)NH2 F 4-Cl H –39.003 –0.907 62.505 252.591 360.425 0.12 0.48 0.10 0.5 0.123 
9x N(C=S)NH2 F 2-Me H –40.094 –0.902 64.64 201.658 338.908 0.12 0.52 0.15 0.25 0.169 
9y N(C=S)NH2 F 3-CF3 H 
–
190.460 
–0.932 53.818 223.300 338.088 0.25 2.59 0.16 0.25 0.584 
9z 
N(C=S)OCH
3 
F H H –70.673 –0.822 61.292 265.441 133.243 0.25 0.65 0.21 0.25 0.406 
9aa 
N(C=S)OCH
3 
F H N –66.071 –0.813 67.096 238.542 167.998 0.12 1.10 0.97 0.12 0.414 
9ab 
N(C=S)OCH
3 
F 3-Cl H –77.372 –0.835 65.448 293.138 131.627 0.12 1.30 0.89 0.12 0.385 
9ac 
N(C=S)OCH
3 
F 3-OMe H 
–
108.607 
–0.813 49.076 289.903 133.527 0.12 2.04 3.46 0.12 0.552 
a MIC = Minimum Inhibitory Concentration for inhibition of the organism shown in µg/mL. 
 
 The constant term in Equation 3 is dominant. Therefore, it is instructive to look at the 
molecular descriptors, based on t value, in the regression model. Descriptors with large |t| values 
are important in the predictive model and, as such, can be examined in order to gain some 
understanding of the nature of the property or activity of interest. The descriptors which had 
higher t-values and which appeared with higher frequency in previous models were selected to 
derive the final regression model. Table 3 indicates the statistical significance of descriptors 
HOF, LUMO and Polarization YY used in the derivation of Equation 3. 
 
Table 3. Descriptors included in the model 
Descriptor Jacknife SEa Covariance SEb t-valuec t-probabilityd 
Heat of formation (X1) 0.0076 0.0032 2.4278 0.0247 
LUMO (X2) 0.8491 0.5157 –4.583 0.0001 
Polarization YY (X3) 0.0245 0.0204 –2.9639 0.0076 
Constant (C) 1.5901    
a An estimate of the standard error on each regression coefficient derived from a jack-knife 
procedure on the final regression model.  
b Gives an estimate of the standard error on each regression coefficient derived from the 
covariance matrix.  
c Measures the significance of each variable included in the final model.  
d Statistical significance for t-values. 
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 The predicted MICs obtained using Equation 3 are shown in Table 2. We found an excellent 
correlation between the predicted and observed MICs. In all three equations we see a good 
correlation of activity with HOF and LUMO energies. Therefore, we made plots of C*HOF 
versus C*LUMO based on Equation 2, where C is a constant coefficient for compounds 8a–8aa 
(Figure 1), and for compounds 8a–8ac based on Equation 3 (Figure 2).  It can be observed in 
these figures that all the compounds that have high HOF and low LUMO energies always have 
superior antibacterial activities. 
 Encouraged by these results, a similar equation (Equation 4) for Enterococcus faecalis (E. fa) 
ATCC 29212 was developed using randomly selected analogues of compounds 8 and 9 in the 
training set.  Compounds 8c, 8f, 8h, 8l, 8z, 9e, 9h, 9k, 9r and 9x made up the test set. 
Compounds 8n, 8w, 8y, 9f were treated as outliers.  Equation 4 is: 
Log (1/C) = 0.0038735112*X1 – 1.5339189*X2 + 0.0022498923*X3 + 0.001369058*  
X4 + 1.272866,            (4) 
where X1 is Heat of Formation; X2 is LUMO; X3 is Octupole XXZ and X4 is Octupole ZZZ 
Component and the statistical parameters for above Equation 4 are: n= 37; s value = 0.36; F = 
65.16; regression coefficient r = 0.93; r^2 = 0.88; cross validation, r^2(CV) = 0.83.  
 
 Activity Increases
      A
ctivity D
ecreases
 
 
Figure 1. Plot of C*HOF vs. C*LUMO of various training and test set of compounds 8. 
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 Once again, a very good correlation between the predicted log (1/C) using Equation 4 and the 
observed log (1/C) was observed for compounds 8 as well as 9 against E. fa ATCC 29212. The 
results are summarised in Tables 1 and 2. The correlation between the observed and the predicted 
antibacterial activities for the training set and the test set for compounds 8 and 9 using Equation 
4 is shown in Figure 3. 
 
 Activity Increases
A
ctivity D
ecreases
 
 
Figure 2. Plot of C*HOF vs. C*LUMO of various training and test set of compounds 9. 
 
 It was expected that such a good correlation between observed and predicted antibacterial 
activities will also exhibit a close correlation with HOF and LUMO energies. An analysis of the 
plots of C*HOF vs C*LUMO (figure and values calculated for C*HOF and C*LUMO from 
Equation 4 are not shown in Tables 1 and 2), where C is a constant coefficient, for compound 8 
and compound 9 for E. fa ATCC 29212, clearly suggests that for both sets of compounds as the 
C*HOF increases and C*LUMO decreases, the antibacterial potency of compounds improves 
and lower MIC values are observed. 
 It would be worthwhile to examine the antibacterial activities of compounds 3–7 in E. fa 
ATCC 29212 and verify if the values predicted (see Table 4) with Equation 4 are comparable to 
the observed MICs. However, to date there is no antibacterial activity data reported for 
compounds 3–7 for E. fa ATCC 29212.  
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Table 4. Prediction of antibacterial activity of N-4-arylacryloylpiperazin-1-yl-phenyl-
oxazolidinones4 
NN N
O
O
F
R1
O
H
N
R2
NN N
O H
N
O
F
R1
R2
3−5 6−7  
 
Compound R1 R2 
H
ea
t o
f 
fo
rm
at
io
n 
LUMO Oct. XXZ Oct. ZZZ 
Predicted 
log (1/C)a  for E. 
fa ATCC 29212 
using Equation 4. 
3a Ph COMe –133.431 –0.836 –79.777 101.405 1.998 
3b 4-PhOH COMe –178.186 –0.793 59.534 5.055 1.940 
3c 3-PhOH COMe –178.257 –0.876 –101.717 294.099 2.100 
3d 2-thiophene COMe –122.886 –1.213 –53.763 211.167 2.825 
3e 3-thiophene COMe –125.282 –1.000 –51.425 30.985 2.248 
3f 2-furan COMe –159.744 –0.858 –0.136 260.705 2.326 
3g 3-furan COMe –161.318 –0.649 32.383 –15.588 1.696 
3h 2-1H-pyrrole COMe –130.927 –0.625 72.798 35.687 1.936 
3i 4-pyridine COMe –125.392 –1.157 –3.427 –125.293 2.382 
3j 3-pyridine COMe –125.499 –1.077 –225.370 37.073 1.983 
3k 3-1H-indole COMe –115.993 –0.623 –11.584 226.867 2.064 
3l 2-methyl–5-furan COMe –168.641 –0.827 –68.720 168.542 1.964 
3m 5-furan-2-carbaldehyde COMe –191.133 –1.244 –344.990 244.203 1.999 
3n 5-furan-2-ylmethanol COMe –204.073 –0.831 18.715 204.752 2.079 
3o 
5-furan-2-ylmethyl 
acetate 
COMe –246.568 –0.966 –396.949 114.470 1.064 
3p 
5-furan-2-carboxylic 
acid 
COMe –246.615 –1.335 –60.717 –419.115 1.654 
3q 2-nitro-5-furan COMe –164.122 –1.800 320.183 –818.085 2.998 
3r 2-nitro-5-thiophene COMe –127.101 –2.178 257.376 
–
1274.840 
2.954 
3s 1,2-difluorobenzene COMe –219.127 –1.257 –53.420 –232.088 1.914 
3t 
(methylsulfonylmethyl)
Ph 
COMe –246.637 –0.973 9.587 295.576 2.236 
3u pyrocatechol COMe –221.837 –0.857 34.598 145.605 2.005 
3v p-phenyl pivalate COMe –227.925 –0.918 –171.486 838.009 2.559 
4a Ph CSMe –62.701 –1.032 239.601 470.589 3.796 
4b 4-PhOH CSMe –108.102 –1.030 434.518 323.365 3.854 
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4d 2-thiophene CSMe –52.838 –1.185 –266.866 105.475 2.430 
4f 2-furan CSMe –88.649 –1.063 –235.789 126.774 2.203 
4i 4-pyridine CSMe –55.413 –1.133 23.571 –39.428 2.796 
4k 3-1H-indole CSMe –45.871 –1.041 279.246 270.114 3.690 
4q 5-nitro-2-furan CSMe –94.655 –1.804 587.221 –677.719 4.066 
5a Ph CSNH2 –58.606 –0.864 306.107 280.574 3.444 
5b 4-PhOH CSNH2 –104.003 –0.868 511.264 111.319 3.503 
5d 2-thiophene CSNH2 –48.822 –1.155 –263.670 2.967 2.267 
5f 2-furan CSNH2 –84.638 –0.909 –228.015 21.757 1.856 
5i 4-pyridine CSNH2 –50.552 –1.111 –183.405 –343.462 1.898 
5k 3-1H-indole CSNH2 –45.035 –0.906 –110.592 132.528 2.421 
5v p-phenyl pivalate CSNH2 –153.077 –0.884 602.704 365.220 3.892 
6 2-furan COMe –122.747 –0.510 0.971 193.289 1.847 
7 2-nitro-5-furan COMe –130.648 –1.380 –308.017 –306.049 1.772 
a C, concentration expressed in mM/L of the drug molecules required for inhibition of 90% 
growth of E. fa ATCC 29212. 
 
 
 
Figure 3. Prediction of antibacterial activity for the training and test set compounds 8–9 against 
E. fa ATCC 29212 using Equation 4. 
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Conclusions 
 
We can conclude that the 3D-QSAR equations based on HOF and LUMO energies enable us to 
predict the MIC value trends of oxazolidinone antibacterials and in many cases obtain close 
correlation with experimental MIC values. Calculation of the values of HOF and LUMO 
energies for compounds containing substitutions can also help to make predictions of 
antibacterial activities closer to experimental MIC values. For example, phenyloxazolidinones 
containing substitutions such as CF3, COCF3, SO2CH3, and SOCHF2 have a very low HOF (large 
negative) and high LUMO energies (high positive). Therefore, we can predict such compounds 
to show poor antibacterial activity based on predicted log (1/C) values from our 3D-QSAR 
equations. Substitutions like CN or NO2 on furan or benzene rings lead to higher HOF (low 
negative value) and low LUMO energies (large negative) and are thus predicted to show good 
antibacterial activity for different sets of compounds and in different bacterial strains. These 
models provide us with a tool to make compounds with predictable antibacterial activities. 
 
 
Experimental Section 
 
General Procedures. TSAR 3D methods were used to derive 3D-QSAR equations as reported 
earlier.4 The structures were sketched using ChemDraw Ultra 5.0 (www.cambridgesoft.com) and 
were exported to TSAR 3.3 (www.accelrys.com). The three-dimensional structures of all the 
molecules were generated. Partial charges were derived using the Charge-2 CORINA 3D 
package in TSAR 3.3 and the geometries of the molecules were optimised using the Cosmic 
module of TSAR. The calculations were terminated if the energy difference or the energy 
gradient were smaller than 1e–005 and 1e–010 kcal/mol respectively. The respective MIC values 
in mg/mL of compounds 8–9 were converted to log (1/C), where C is the concentration 
expressed in mM/L of the drug molecule required for 90% inhibition of the growth of the 
microorganism. Data for inactive compounds in the ranges >16 µg/mL, >32 µg/mL and >64 
µg/mL are treated as = 16 µg/mL, 32µg/mL and 64µg/mL, respectively, for the training data set 
and r^2 determination.  
Molecular descriptors for the entire molecules were calculated with TSAR 3.3. Vamp, a 
semiempirical molecular orbital package in TSAR 3.3, was used to calculate electronic 
properties, including heats of formation, HOMO and LUMO energies, polarizability and 
multipole components, and to perform structure optimizations in vacuo using default parameters 
and using the Hamiltonian method PM3. Descriptors with the same values for all compounds 8–
9 were discarded. A pair-wise correlation analysis of the remaining descriptors was performed. 
Regression models were built using descriptor subsets containing only one of these highly 
correlated descriptors. To develop QSAR models, stepwise MLR analysis with leave-one-out 
(LOO) cross-validation was applied to the data set. The approach used for the prediction of 
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antibacterial activities is a simple regression analysis. We refer to these procedures as 3D QSAR 
methods. 
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